Literature DB >> 25642730

Delivery of lipid micelles into infarcted myocardium using a lipid-linked matrix metalloproteinase targeting peptide.

Juliane Nguyen1, Richard Sievers2, J P Michael Motion3, Saul Kivimäe3, Qizhi Fang2, Randall J Lee2.   

Abstract

There is a great need for delivery strategies capable of efficiently localizing drugs to the damaged myocardium that do not require direct intramyocardial injection of therapeutic molecules. In the work discussed here, we exploited the myocardium-specific upregulation of matrix metalloproteinases (MMPs) that occurs during myocardium remodeling by designing a micellar vehicle containing an MMP-targeting peptide (MMP-TP). The binding of MMP-TP to MMP was evaluated with purified MMP-2 protein and U-937 cells induced to overexpress MMP. Inhibition of MMP-2 activity was not observed in the presence of unmodified micelles but was pronounced at a 5 mol % MMP-TP ligand density. In a FACS analysis, MMP-TP micelles containing 5 mol % of the MMP-targeting peptide showed ∼10-fold higher binding to activated U937 cells than plain micelles and micelles containing a control peptide with two amino acid replacements. MMP-TP-micelles and plain micelles were injected intravenously into C57BL/6 mice 1, 3, and 7 days after the induction of a myocardial infarction (MI). Immunohistochemistry performed on heart tissue sections revealed that MMP-TP-micelles colocalize with both MMP and infiltrating macrophages. MMP-TP micelles showed significantly enhanced accumulation to the necrotic area of the heart after MI on days 3 and 7 when compared to plain micelles and negative control peptide micelles. This is coincident with the measured temporal profile of MMP gene expression in the heart after MI. These results suggest that MMP-TP micelles are candidates for the development of targeted regenerative heart therapeutics because of their ability to target the infarcted myocardium in a MMP dependent manner.

Entities:  

Keywords:  drug targeting; matrix metalloproteinase; myocardial infarction; targeted micellar vehicles

Mesh:

Substances:

Year:  2015        PMID: 25642730     DOI: 10.1021/mp500653y

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  13 in total

1.  Modulating Macrophage Polarization through CCR2 Inhibition and Multivalent Engagement.

Authors:  Michael B Deci; Scott W Ferguson; Sydney L Scatigno; Juliane Nguyen
Journal:  Mol Pharm       Date:  2018-06-04       Impact factor: 4.939

2.  Flow arrest intra-arterial delivery of small TAT-decorated and neutral micelles to gliomas.

Authors:  Juliane Nguyen; Shaolie S Hossain; Johann R N Cooke; Jason A Ellis; Michael B Deci; Charles W Emala; Jeffrey N Bruce; Irving J Bigio; Robert M Straubinger; Shailendra Joshi
Journal:  J Neurooncol       Date:  2017-04-18       Impact factor: 4.130

3.  Cationizable lipid micelles as vehicles for intraarterial glioma treatment.

Authors:  Juliane Nguyen; Johann R N Cooke; Jason A Ellis; Michael Deci; Charles W Emala; Jeffrey N Bruce; Irving J Bigio; Robert M Straubinger; Shailendra Joshi
Journal:  J Neurooncol       Date:  2016-02-22       Impact factor: 4.130

4.  MiR-101a loaded extracellular nanovesicles as bioactive carriers for cardiac repair.

Authors:  Jinli Wang; Christine J Lee; Michael B Deci; Natalie Jasiewicz; Anjali Verma; John M Canty; Juliane Nguyen
Journal:  Nanomedicine       Date:  2020-04-08       Impact factor: 5.307

Review 5.  Nanocarrier-Based Targeted Therapies for Myocardial Infarction.

Authors:  Thomashire A George; Chuan-Chih Hsu; Annette Meeson; David J Lundy
Journal:  Pharmaceutics       Date:  2022-04-25       Impact factor: 6.525

6.  Enzyme-Responsive Nanoparticles for Targeted Accumulation and Prolonged Retention in Heart Tissue after Myocardial Infarction.

Authors:  Mary M Nguyen; Andrea S Carlini; Miao-Ping Chien; Sonya Sonnenberg; Colin Luo; Rebecca L Braden; Kent G Osborn; Yiwen Li; Nathan C Gianneschi; Karen L Christman
Journal:  Adv Mater       Date:  2015-08-25       Impact factor: 30.849

7.  Targeting delivery of Radix Ophiopogonis polysaccharide to ischemic/reperfused rat myocardium by long-circulating macromolecular and liposomal carriers.

Authors:  LiNa Wang; ChunXia Yao; Fei Wu; Xiao Lin; Lan Shen; Yi Feng
Journal:  Int J Nanomedicine       Date:  2015-09-10

8.  Distribution of Systemically Administered Nanoparticles Reveals a Size-Dependent Effect Immediately following Cardiac Ischaemia-Reperfusion Injury.

Authors:  David J Lundy; Kun-Hung Chen; Elsie K-W Toh; Patrick C-H Hsieh
Journal:  Sci Rep       Date:  2016-05-10       Impact factor: 4.379

9.  Nanoparticle delivery of cardioprotective therapies.

Authors:  Abraham Mendez-Fernandez; Hector A Cabrera-Fuentes; Bhaarathy Velmurugan; Jason Irei; William A Boisvert; Shengjie Lu; Derek J Hausenloy
Journal:  Cond Med       Date:  2020-02

10.  Protective effects on myocardial infarction model: delivery of schisandrin B using matrix metalloproteinase-sensitive peptide-modified, PEGylated lipid nanoparticles.

Authors:  Mingfeng Shao; Wenfang Yang; Guangying Han
Journal:  Int J Nanomedicine       Date:  2017-09-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.